The immune system has long been recognised as playing a central role in the organism's defence against infectious diseases and possibly the development of neoplasia. Antibodies represent a set of molecules that exhibit extraordinary specificity and selectivity. This has been appreciated since the work of Landsteiner,' who, in the early years of this century, was able to provide examples such as the ability of an antiserum to resolve the d and 1 stereoisomers of a simple aliphatic molecule, tartaric acid. More complex organic compounds that vary only by a single substituent group (such as the steroids, or digoxin and digitoxin, which differ in one hydroxyl group) may be readily separated.2 The general structure of the antibody molecule is remarkably conserved, so that it is difficult for the chemist to tell the difference between two antibodies of varying specificity. There is a small region of the molecule, however, that is highly variable in its structure (the complementarity region) and makes up the surface that binds antigen. It is the amino acid sequence in this complementarity region that determines the nature of the antigen recognised.
SUMMARY
The immune system has long been recognised as playing a central role in the organism's defence against infectious diseases and possibly the development of neoplasia. The active stimulation of the immune system by immunisation and the passive administration of antitoxins have a venerable history in medicine. Yet the concept that antibodies may be used to modify physiological or pharmacological effects or may act as diagnostic agents in the living organisms has only recently come to be recognised. Advances, both in an understanding of the structural chemistry of the antibody molecule and in the ability to culture antibody-producing cells, now permit the selection and production of homogeneous antibodies and their smaller fragments in quantity by means other than conventional immunisation. These innovations will allow the development of a new pharmacology based on the remarkable resolving power of the antibody combining site. Antibodies or their fragments are shown to inhibit the pressor action of renin, to neutralise the pharmacological actions of digitalis, to block the beta-adrenergic receptor, and to detect and image myocardial infarcts.
Antibodies represent a set of molecules that exhibit extraordinary specificity and selectivity. This has been appreciated since the work of Landsteiner,' who, in the early years of this century, was able to provide examples such as the ability of an antiserum to resolve the d and 1 stereoisomers of a simple aliphatic molecule, tartaric acid. More complex organic compounds that vary only by a single substituent group (such as the steroids, or digoxin and digitoxin, which differ in one hydroxyl group) may be readily separated. 2 The general structure of the antibody molecule is remarkably conserved, so that it is difficult for the chemist to tell the difference between two antibodies of varying specificity. There is a small region of the molecule, however, that is highly variable in its structure (the complementarity region) and makes up the surface that binds antigen. It is the amino acid sequence in this complementarity region that determines the nature of the antigen recognised.
Recent work has uncovered the mechanisms responsible for variation in the amino acid sequence of the complementarity region. The Accepted for publication 7 September 1981 genes: V, which occurs in several hundred copies, and J, of which four copies have been identified.3-6 V and J of the light chain may occur in any combination. The heavy chain's variable region is the product of three genes: V, in several hundred copies, D, in 10 or more copies, and J, in four copies.78 As in the light chain, any permutation and/or combination of these genes may occur. These mechanisms alone account for 107 19 in our laboratory purified canine renin some 600 000-fold in an eight-step process that yielded a product homogeneous by several criteria. Antibodies specific for purified canine renin produced in a goat inhibited the pressor action of the enzyme but did not modify the capacity of either angiotensin I or II to raise blood pressure.20 This antibody preparation did not have any effect on the haemodynamics of the unanaesthetised, sodium-replete dog, while a significant hypotensive effect was noted in the sodium-depleted dog when the immunoglobulin G fraction from an antiserum was injected intravenously. Parallel to the fall in blood pressure, a decrease in both plasma renin activity and angiotensin II concentrations was observed, indicating that the antibody was exerting its effect by inhibiting the enzymatic action of renin on its substrate.
Intact antibody has a number of troublesome properties when used as a drug. When the source is a heterologous species, it is an immunogen. After the first use, an immune response develops that may result in anaphylaxis, serum sickness, or at best accelerated elimination. Pharmacological effects may be very persistent, because antibody is eliminated either by metabolism or by the immune system if sensitisation has occurred. The half-life for endogenous immunoglobulins may be measured in days or weeks depending on the species studied, the immunoglobulin's isotype, and whether or not the recipient has been immunised. When there is concern about renal function, the presence of immune complexes is likely to cloud interpretation. In haemodynamic studies, vasoactive peptides released by activation of complement may have independent effects, particularly on haemodynamics.
Some of these problems may be minimised by producing antibody fragments. Renin-specific Fab has been used.to block the action of renin in both sodium-depleted unanaesthetised dogs as well as in uninephrectomised dogs made hypertensive by constriction of the renal artery. In both models, intravenous injection of Fab results in a hypotensive response (Fig. 1 ). When compared with intact antibody, the initiation of hypotension by Fab is more rapid, and the duration very much shorter. Repetitive experiments have been possible in the same animal without the problem of anaphylaxis that had been experienced previously when intact antibody had been used.
An antiserum is a mixture of several hundreds of antibodies, all capable of binding to the immunising antigen. These antibodies vary considerably both with respect to affinity for the antigen and specificity of recognition. The mixture of antibodies contained within an antiserum is different among even inbred (genetically identical) individual animals, as it is in the sera of a single animal collected at varying times after immunisation. Supplies of antisera are necessarily limited. Kohler and Milstein9 showed that antibodies might be produced in a very different manner. The technique of somatic-cell fusion allows for the production of hybrid cells. If the precursors of the hybrid are normal lymphocytes and cells from a malignant plasmacytoma, one can incorporate both properties of antibody production and growth in vitro into the product (colloquially named "hybridoma"). Cells that grow in culture may be cloned, so that all the progeny are daughters of a single precursor cell. A homogeneous culture of this type produces a single antibody that is uniform in structure and antigen binding prop- erties. Since the cultures may be stored indefinitely at low temperatures, the same antibody may always be recovered. The amount of renin-specific antibody available from conventional sera was severely limited; we set out, therefore, to make monoclonal reninspecific antibodies by the somatic-cell fusion method,22 making production in industrial quantities possible. Fig. 2 shows the binding to immobilised renin by a monoclonal antibody. We look forward to using monoclonal antibodies as more specific reagents that are available in indefinite quantities in the dissection of the physiology and chemistry of the reninangiotensin system.
Blockade of beta-adrenergic receptor
The hormone receptors of the cell's plasma cell membrane are present in a very small number of copies (10 000 There is a wide variety of structurally different beta-antagonists available. All, however, share a common structure, a propanolamine side chain. Rabbits were immunised with the beta-antagonist alprenolol conjugated to a protein. The resulting antiserum was passed over an affinity column to which another beta-antagonist had been linked and aU that was not bound was discarded. The column was then washed with I-propranolol and the eluted antibody retained. Fig. 3 shows the specificity profile of this antibody fraction. Several beta-adrenergic antagonists as well as agonists are bound with considerable affinity, in some cases similar to that of the receptor. This fraction also resolved 1 and d stereoisomers of isoprenaline (not shown). Thus the antibody fraction could be viewed as a qualitative, but not a strictly precise quantitative, model for the beta-adrenergic receptor. 
Imaging of myocardial infarcts using cardiac myosin-specific antibodies
The hallmark of cell death is loss of the membrane integrity: when there is no longer a physical separation between inside and outside, the cell ceases to exist. This principle is commonly employed in clinical practice in diagnosing tissue infarction. Intracellular enzymes are lost to extracellular fluid, and their increased concentration in the blood may be used as a measure of tissue necrosis. An alternative approach is the inward diffusion of a marker that is normally excluded from cells. We have selected myocardial infarction as a model and radioactively labelled myosin-specific antibody as a marker.
Myosin is the principal protein of the cardiac cell. Its covalent structure is unique to the heart,29 allowing the development of antibodies that differentiate between cardiac and either skeletal-or smooth-muscle myosins. In the intact organism, cardiac myosin is protected from extracellular fluid by the cell's plasma membrane. When cell death occurs and the membrane breaks down, myosin is exposed to extracellular fluid. It is then available to react with labelled antibodies or antibody fragments.
A visual demonstration of this phenomenon is seen in Fig. 4 . The figure shows a scanning electron micrograph of part of a neonatal mouse cardiac myosite that had been rendered ischaemic by prolonged exposure to nitrogen and then incubated with 1 A diameter, polystyrene spheres covalently bound to myosinspecific antibody. Myofibrils are seen protruding from a hole in the cell membrane. Antibody-coated microspheres clearly bind to the myofibrils. Not only is myosin very insoluble in physiological fluids so that membrane breakdown does not result in antigen loss, but it persists for considerable periods after ischaemic necrosis.30 This should allow for identification of infarcted myocardium in days to, perhaps, several weeks after the initial event. In our initial exploration of this concept, a canine myocardial infarction model was used. 31 The left anterior descending coronary artery was ligated, and four hours later I25I-labelled, myosin-specific antibody or antibody fragments were injected intravenously. At varying times after the injections, the animals were killed, the hearts were perfused with triphenyltetrazolium chloride, and the myocardia examined.32 Fig. 5 (left) shows a section of a heart treated in this way. The light area represents a largely subendocardial infarction. The central panel of the figure is a tracing of the slice superimposed on an autoradiograph. The exposed area corresponds to the infarct as disclosed by the triphenyltetrazolium stain. The right panel shows specific radioactivity in the area of the infarct relative to myocardium on the posterior wall. It is apparent that the major concentra- Microautoradiographs showed that individual necrotic myosites could be identified and differentiated from adjacent viable cells.33 In order to show that antibody concentration was specific and not simply the result of passive diffusion of a macromolecule into infarcted cells, specific antibody labelled with 1311 and nonimmune globulin labelled with 125I were injected simultaneously into the coronary arteries.32 At the centre of the infarct, the antibody has concentrated 34-fold in relation to normal myocardium, while the nonimmune globulin is only sevenfold in excess. In normal tissue, as expected, concentrations are equal. When compared to a marker of relative flow, the distribution of radioactive microspheres which had been injected into the left atrium, it was clear that the concentration of labelled antibody was inversely related to relative blood flow.31 32 There seems to be sufficient collateral circulation in this ischaemic model Imnological probes in cardiovascular disease to provide for delivery of antibody, even to the regions of minimal blood flow. It would be very desirable to apply this method to the detection, localisation, and quantification of myocardial infarcts in the living subject.
Optimal imaging with a gamma or positron camera requires the labelling of antibodies with radionucides of appropriate half-life and affinity. We have accomplished this by covalently linking diethylene triamine penta-acetic acid (DTPA) to antibody or antibody fragment and then binding cationic radionuclides by chelation.34 Successful images have been obtained using the following radionuclides linked to antibody: "lIn-DTPA-Ab Fab,34 68Ga-DTPA Fab,35 and 99mTc-DTPA-Ab Fab. 34 An example of a positron image of an anterior infarct in a living dog using 68Ga-labelled antibody is shown in Fig. 6 (left) . The positron imaging technique allows for tomographic reconstruction and, thus, the heart is visible on cross-section in the "3N-ammonia image in the centre panel of Fig. 6 (ammonium ion is a potassium analogue and concentrates in normal tissue). On the left side of the image there is clearly less density, reflecting the region of infarction. Superimposition of the 13N and the 68Ga images (right panel) showed that the antibody was concentrated directly in the area of diminished ammonium ion uptake. The potential for applying this method to the evaluation of myocardial infarcts in a clinical setting seems very great indeed since it offers high specificity and resolution.
Reversal of digitalis glycoside intoxication
If the effect of an endogenously produced hormone can be reversed, it should also be possible to counteract the undesirable effects of an exogenously administered drug or toxin. The digitalis glycosides are of great value in the treatment of congestive heart failure and consequently are frequently used in clinical medicine. Unfortunately, they are characterised by a very close toxic-therapeutic ratio. Digitalis intoxication is one of the most frequent adverse drug reactions reported. There is no specific antidote, and the cardiac arrhythmias that are a feature of digitalis intoxication are not uncommonly fatal.
We reasoned that if an antibody specific to the digitalis glycosides had a higher affinity for the drug than the physiological receptor, it should be possible to transfer the ligand from the receptor to antibody, simply by mass action. For optimal effectiveness diffusion distances should be minimal, and the antibody should be in high concentration in extracellular fluid in proximity to the receptor. It would also be desirable to remove the antibody-drug complex rapidly from the body. Both aims may be accomplished by the use of digitalis-specific Fab. As indicated above, the volume of distribution of Fab is greater than intact antibody since it readily enters extracellular fluid. It is also of sufficiently small size (50 000 Daltons) to pass through the glomerular filter and be largely excreted in the urine. 36 Digoxin-specific antibody was purified from sheep antiserum using immobilised ouabain Fab isolated after papain cleavage. 3 After demonstration of safety and effectiveness in animal studies, clinical investigations were initiated. At the time of this writing, 17 patients with life-threatening digitalis intoxication have been studied. The patients ranged in age from Fig. 6 68Ga and 13NH4+ were obtained sequentially using a positron camera; S mCi of 13NH4+ was administered intraveo(y to a dog that had had occlusion ofthe distal segment ofthe left anterior descending arteryforfour hours and was imaged (centre); 30 31-8.) infants to septuagenarians and in each case a dramatic reversal of the signs and symptoms of intoxication occurred. [38] [39] [40] The history of a recently reported patient is typical of the group.39 She was a 34-year-old wife of a physician, who, because of marital difficulties, took 20 mg digitoxin, a massive overdose. She appeared well on admission to the hospital except for nausea, but soon lapsed into a series of life-threatening arrhythmias that included multiple episodes of ventricular fibrillation, which were treated with countershock, as well as asystole, which was treated by ventricular pacing. At the time the antibody Fab became available to the physicians treating her, the patient was in shock and anuric, and she had dilated pupils. Her serum potassium was raised, a grave prognostic sign in digitalis intoxication.4' Within an hour after the intravenous administration of antibody Fab, her atrioventricular conduction had returned, and she was soon in normal sinus rhythm. No further arrhythmias occurred. She was discharged from hospital without sequelae several days later. Fig. 7 tissue-bound drug equilibrated with the antibody (antibody-bound drug is pharmacologically inactive), followed by rapid clearance of both drug and Fab. It should be noted that the half-life of digitoxin in man is normally three and a half days when hepatic metabolism of the drug is the major source of removal. It is apparent that excretion was much accelerated by the antibody Fab, the half-life apparently reduced to about 12 hours. Fig. 8 shows that both antibody and Fab appear in the urine in largest amounts within the first day after Fab administration. The digitalis glycosides in most common use are digoxin and digitoxin. They differ fror one another very little in their chemical structure, yet most antibodies differentiate between them, with differences in affinity of 50-to 100-fold.2 It would be desirable to use an antibody that bound both digoxin and digitoxin with equal affinity. A monoclonal antibody (designated 26-10 in our laboratory) was selected that had an affinity of 5 While some of the advantages of antibodies are obvious, the disadvantages, discussed in part above, must also be considered. When binding to a specific site is all that is desired, the activation of the biological effects that are an intrinsic part of an immune reaction is undesirable. The smaller Fab that was discussed above as a' possible solution to some of these problems still carries with it an entire domain (one half of its mass) that is of no relevance to antigen binding. Fab from a heterologous species, while of diminished immunogenicity, is likely to cause hypersensitivity when used on a long-term basis. The solutions to these problems are almost at hand. A much smaller fragment of antibody has been produced that retains all the binding energy and specificity of the intact molecule. Fv comprises a single domain and has a molecular size of 25 000 Daltons. 44 While its pharmacokinetics have not as yet been mined, I anticipate that it will be very rapidly deared and distributed. The advent of the hybridoma method will make possible not only the selection and large-scale production of antibodies of uniform properties, but also the reduction or elimination of the potential problem of hypersensitivity, since it will be possible, as indicated above, to produce human antibodies. Will the formation of anti-idiotypic antibodies defeat the long-term utility of antibody therapy? I believe that the well-recognised difficulty in producing anti-idiotypes, even deliberately, indicates that this problem will be rare. The next decade will see a new pharmacology based on the antibody combining site. cardiovascular disease. 
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